Epizyme Inc (EPZM) Given Average Rating of “Buy” by Analysts

Epizyme Inc (NASDAQ:EPZM) has been given a consensus rating of “Buy” by the eleven analysts that are currently covering the company. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.20.

A number of analysts recently commented on EPZM shares. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Wednesday, December 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price objective (down previously from $26.00) on shares of Epizyme in a research note on Saturday, March 11th. Cann reaffirmed an “outperform” rating and set a $26.00 price objective on shares of Epizyme in a research note on Wednesday, April 12th. Oppenheimer Holdings Inc. started coverage on Epizyme in a research note on Thursday, April 13th. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, CIBC reaffirmed an “outperform” rating on shares of Epizyme in a research note on Thursday, April 13th.

ILLEGAL ACTIVITY NOTICE: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://transcriptdaily.com/2017/04/22/epizyme-inc-epzm-given-average-rating-of-buy-by-analysts.html.

In other news, CFO Andrew E. Singer sold 2,013 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $17.09, for a total value of $34,402.17. Following the transaction, the chief financial officer now directly owns 36,175 shares in the company, valued at approximately $618,230.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Robert A. Copeland sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, April 4th. The stock was sold at an average price of $16.36, for a total value of $81,800.00. Following the completion of the transaction, the insider now owns 33,538 shares in the company, valued at $548,681.68. The disclosure for this sale can be found here. Company insiders own 25.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in EPZM. Metropolitan Life Insurance Co. NY increased its position in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Epizyme by 17.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 40,387 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 5,919 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Epizyme during the fourth quarter valued at approximately $351,000. Citadel Advisors LLC bought a new stake in shares of Epizyme during the third quarter valued at approximately $289,000. Finally, Rock Springs Capital Management LP increased its stake in shares of Epizyme by 7.5% in the third quarter. Rock Springs Capital Management LP now owns 642,500 shares of the biopharmaceutical company’s stock valued at $6,322,000 after buying an additional 45,000 shares during the last quarter. Institutional investors own 79.98% of the company’s stock.

Epizyme (NASDAQ:EPZM) traded down 2.68% during trading on Thursday, hitting $14.55. 177,054 shares of the company’s stock were exchanged. Epizyme has a 12-month low of $7.02 and a 12-month high of $17.80. The company’s 50-day moving average price is $15.93 and its 200 day moving average price is $12.20. The firm’s market cap is $847.51 million.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Thursday, March 9th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.05. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.61 million. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. Equities analysts forecast that Epizyme will post ($2.55) earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).